IPR decision: Dec. 08, 2020
|
AIA Review # |
Filing Date |
Institution Date |
Petitioner |
Patent |
Respondent |
Status |
|
IPR2020-01045 |
06/10/2020 |
09/01/2020 |
Teva |
7,326,708 |
Merck |
Terminated-Settled |
Note: Mylan already filed IPR on US’708 patent on 10/30/2019 and PTAB instituted IPR on 05/12/2020. DRL & Sun also filed IPRs (IPR2020-01060 & IPR2020-01072) which were instituted on 09/01/2020.
US 7,326,708 (Merck & Co.; Exp: 05/24/2027 with
PED):
1. A dihydrogenphosphate salt of
4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine
of structural formula I:##STR## or a hydrate thereof.
No comments:
Post a Comment